| ADC Therapeutics–SEVERAL: investment, 201906–201907 financing round Series E expansion $103m bringing total Series E to $303m |
2019-06-12 |
| ADC Therapeutics–SEVERAL: investment, 201909–201910 IPO up to approx $230m at NYSE WITHDRAWN 10/19 |
2019-09-06 |
| ADC Therapeutics–SEVERAL: investment, 202004–202005 IPO at NYSE $267.6m with 14.1m shares at $19/share |
2020-04-24 |
| Adcendo–Pontifax: investment, 202304 financing round Series A extension totalling €31m incl new + co-lead investor Pontifax Venture Capital |
2023-04-04 |
| Adcendo–RA Capital: investment, 202104 financing round Series A totalling €51m incl co-investor RA Capital Management |
2021-04-29 |
| Adcendo–RA Capital: investment, 202304 financing round Series A extension totalling €31m incl existing + co-investor RA Capital Management |
2023-04-04 |
| Adcendo–SEVERAL: investment, 202104 financing round Series A €51m co-led by Novo Seeds + Ysios Capital |
2021-04-29 |
| Adcendo–SEVERAL: investment, 202304 financing round Series A extension €31m bringing total Series A to €82m |
2023-04-04 |
| Addex–SEVERAL: investment, 201802–201803 private placement CHF40m with 12.78m new shares at CHF3.13/share plus 0.4 warrants at CHF3.43 |
2018-02-15 |
| Addex–SEVERAL: investment, 201909– filing of Nadaq lisiting of ADSs (without proposing to register any new issuance of secutiries) |
2019-09-24 |
| Addex–SEVERAL: investment, 202101 capital increase global offering $11.5m with 6.9m new shares (thereof 6.75m in form of ADSs |
2021-01-11 |
| Adendra Therapeutics–Apple Tree Partners: investment, 202112 founding Series A investment £40m from ATP Life Sciences UK |
2021-12-07 |
| Adeptrix–Bruker: investment, 202101 financing round Series A incl new + minority investor Bruker Corp |
2021-01-06 |
| Adeptrix–SEVERAL: investment, 202101 financing round Series A closed with new + minority investor Bruker Corp |
2021-01-06 |
| ADF/IDF–Symrise: investment, 201901– acquisition $900m by Symrise ANNOUNCED |
2019-01-31 |
| Adhesys Medical–Grünenthal: investment, 201704 acquisition of Adhesys by Grünenthal |
2017-04-07 |
| Adhesys Medical–GSK Stockmann: legal services, 201704 supply legal advisor for sale of Adhesys Medical to Grünenthal |
2017-04-07 |
| Adocia–Ruth Group: public relations, 201807 service existent IR USA by The Ruth Group |
2018-07-18 |
| AdoRx–Epidarex Capital: investment, 201806 1st financing round totalling $10m from Epidarex Capital + CRT Pioneer Fund |
2018-06-21 |
| Aduro Biotech–Univ Bonn: cancer immunotherapy, 201704– license for STING agonists via Provendis to Aduro Biotech |
2017-04-27 |
| Advanced Accelerator Applications–Novartis: investment, 201710–201801 cash tender offer $3.9b with $41/ordinary share |
2017-10-30 |
| Advanced Analytical–Agilent: investment, 201803–201805 acquisition $250m in cash of Advanced Analytical Technologies Inc by Agilent |
2018-03-07 |
| Advanced Liquid Logic–CEA: microfluidics technology, 201307 before license from CEA for EWOD microfluidics technology |
2013-07-01 |
| AdvanDx–OpGen: investment, 201507 merger acquisition by AdvanDx for 682k shares of OpGen common stock |
2015-07-14 |
| Advent France Biotechnology–Advent Life Sciences: fund management, 201704 service existent support by Advent Life Sciences |
2017-04-20 |
| Advent France Biotechnology–SEVERAL: investment, 201704 first closing €64.75m of Advent France Biotechology Seed-Fund I |
2017-04-20 |
| Advent Life Sciences–Scius Communications: public relations, 202205 supply service existent by Scius Communications |
2022-05-26 |
| Adverum Biotechnologies–Synpromics: genomic technology, 201801 collab existent |
2018-01-17 |
| Aelis Farma–NewCap: public relations, 201912 service existent by NewCap |
2019-12-13 |
| Aelis Farma–SEVERAL: grant, 201912c research grants totalling €9m from various organisations incl US NIDA |
2019-12-13 |
| Aelis Farma–SEVERAL: investment, 201912 financing round €11m incl Region Nouvelle Aquitaine + Inserm Transfert Initiative + Bpifrance |
2019-12-13 |
| Aeovian Pharmaceuticals–Apollo Health Ventures: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Apollo HV |
2019-10-03 |
| Aeovian Pharmaceuticals–Evotec: investment, 201910 financing round Series A totalling $37m incl founding + co-investor Evotec |
2019-10-03 |
| Aeovian Pharmaceuticals–MacDougall Biomedical Communications: public relations, 201910 service existent by MacDougall |
2019-10-03 |
| Aeovian Pharmaceuticals–SEVERAL: investment, 201910 financing round Series A $37m led by VenBio + Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–Sofinnova: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor Sofinnova Investments |
2019-10-03 |
| Aeovian Pharmaceuticals–VenBio: investment, 201910 financing round Series A totalling $37m incl new + co-lead investor VenBio Partners |
2019-10-03 |
| Aerium Therapeutics–F-Prime: investment, 202203 financing round Series A incl new + co-investor F-Prime Capital |
2022-03-22 |
| Aerium Therapeutics–Omega Funds: investment, 2021 seed investment + incubation of Aerium by Omega Funds |
2021-01-01 |
| Aerium Therapeutics–Omega Funds: investment, 202203 financing round Series A incl existing seed + lead investor Omega Funds |
2022-03-22 |
| Aerium Therapeutics–SEVERAL: investment, 202203 emerges with substantial financing round Series A led by seed investor Omega Funds |
2022-03-22 |
| Aerovate Therapeutics–SEVERAL: investment, 202008 financing round Series A $72.6m |
2020-08-01 |
| AexeRNA Therapeutics–BioNTech: investment, 202310 acquisition €na of AexeRNA by BioNTech |
2023-10-01 |
| AexeRNA Therapeutics–Linden Lake Venture Capital: investment, 202010 co-founding investor Linden Lake Venture Capital |
2020-10-01 |
| Affimed–SEVERAL: investment, 201701 public offering $18m + $2.7m with 10m+1.5m common shares at $1.8/share |
2017-01-19 |
| Affimed–SEVERAL: investment, 201802 public offering $26.5m ($24.5m net) with 12.5m+1.725m common shares at $2/share |
2018-02-12 |
| Affimed–SEVERAL: investment, 202101 public offering $100m+$15m with 16.7m+2.5m common shares at $6/share |
2021-01-12 |
| Affimed–SEVERAL: investment, 202204 public offering $90m+$13.5m with 22.5m+3.375m common shares at $4/share PRICED |
2022-04-12 |
| Affimed–SVB: credit, 202101–202511 up to €25m loans in three tranches with €10m at closing plus €15m milestone-based |
2021-01-11 |
| Affimed–Univ Texas: cancer immunotherapy, 201701– collab clinical + commerc to evalaute TandAbs with natural killer cell product of MD Anderson |
2017-01-04 |
| Affini-T Therapeutics–Agent Capital: investment, 202203 financing round totalling $175m incl co-investor Agent Capital |
2022-03-22 |
| Affini-T Therapeutics–Alexandria Real Estate: investment, 202203 financing round totalling $175m incl co-investor Alexandria Venture Investments |
2022-03-22 |
| Affini-T Therapeutics–Bayer: investment, 202203 financing round totalling $175m incl co-lead investor Leaps by Bayer |
2022-03-22 |
| Affini-T Therapeutics–Catalio Capital: investment, 202203 financing round totalling $175m incl co-investor Catalio Capital Management |
2022-03-22 |
| Affini-T Therapeutics–Erasca Ventures: investment, 202203 financing round totalling $175m incl co-investor Erasca Ventures |
2022-03-22 |
| Affini-T Therapeutics–Fred Hutchinson: investment, 202203 financing round totalling $175m incl co-investor Fred Hutchinson Cancer Research Center |
2022-03-22 |
| Affini-T Therapeutics–Humboldt Fund: investment, 202203 financing round totalling $175m incl co-investor Humboldt Fund |
2022-03-22 |
| Affini-T Therapeutics–Parker Institute: investment, 202203 financing round totalling $175m incl co-investor Parker Institute for Cancer Immunotherapy |
2022-03-22 |
| Affini-T Therapeutics–SEVERAL: investment, 202203 financing round $175m co-led by Vida Ventures + Leaps by Bayer |
2022-03-22 |
| Affini-T Therapeutics–Vida Ventures: investment, 202203 financing round totalling $175m incl co-lead investor Vida Ventures |
2022-03-22 |
| Affinia Therapeutics–Alexandria Real Estate: investment, 202003 financing round Series A totalling $60m incl existing + co-investor Alexandria VI |
2020-03-31 |
| Affinia Therapeutics–Atlas Venture: investment, 202003 financing round Series A totalling $60m incl new + co-lead investor Atlas Venture |
2020-03-31 |
| Affinia Therapeutics–F-Prime: investment, 202003 financing round Series A totalling $60m incl existing + co-lead investor F-Prime Capital |
2020-03-31 |
| Affinia Therapeutics–Lonza: AAV technology, 202003 license existent from Lonza + Massachusetts Eye and Ear |
2020-03-31 |
| Affinia Therapeutics–Lonza: investment, 202003 financing round Series A totalling $60m incl existing + co-investor Lonza |
2020-03-31 |
| Affinia Therapeutics–New Enterprise Associates: investment, 202003 financing round Series A totalling $60m incl existing + co-lead investor NEA |
2020-03-31 |
| Affinia Therapeutics–Partners HealthCare: investment, 202003 financing round Series A totalling $60m incl existing + co-investor Partners Innovation |
2020-03-31 |
| Affinia Therapeutics–SEVERAL: investment, 202003 financing round Series A $60m co-led by Atlas Venture + F-Prime Capital + NEA |
2020-03-31 |
| Affinivax–GSK: investment, 202205– acquisition 100% for $2.1b upfront + $1.2b milestones by GSK ANNOUNCED |
2022-05-31 |
| Affinivax–SEVERAL: investment, 202004 financing round Series B $120m |
2020-04-01 |
| Agalimmune–BioLineRx: investment, 201703 acquistion $3m cash upfront + $3m shares + milestones of Agalimmune by BioLineRx |
2017-03-23 |
| AgBiome–ElevateBio: investment, 202011–202110 acquisition of Life Edit Therapeutics from AgBiome Delta LLC |
2020-11-16 |
| Agena Bioscience–Mesa Labs: investment, 202109– acquisition $300m in cash of Agena by Mesa Laboratories ANNOUNCED |
2021-09-14 |
| Agendia–Inivata: cancer test, 202104– co-excl distribution rights €na for RaDaR liquid biopsy assay for breast cancer in North America + Europe |
2021-04-28 |
| Agendia–Instinctif Partners: public relations, 201706 service existent by Instinctif Partners |
2017-06-02 |
| Agenus–JSR Corp: cell line development, 201901– collab expansion license to use Selexis’ SUREtechnology for production of therapeutic proteins |
2019-01-09 |
| Agenus–KKH Advisors: public relations, 202203 service existent by KKH Advisors |
2022-03-07 |
| AgeX Therapeutics–Forever Healthy: investment, 202101 existent investment of Kizoo Technology Capital |
2021-01-25 |
| Agilent–Akoya Biosciences: IHC diagnostics, 202301– collab developm + marketing solutions integrating Dako Omnis instrument + PhenoImager HT system |
|
| Agilent–AMETEK: FTIR analyzer, 201807 collab developm + manufacturing Miniscan IR LOG FTIR analyzer for in-field oil/grease analysis |
2018-07-18 |
| Agilent–Atturos: mass spectrometry, 201604– academic collaboration agreement |
2016-04-01 |
| Agilent–BioTek Instruments: cell analysis technology, 201804– collab marketing integrated solution Seahorse XFe analyzer with Cytation 1 reader |
2018-04-04 |
| Agilent–e-MSion: mass spectrometry technology, 2019– collab co-marketing of ExD cell technology with 6500 Series LC-/Q-TOF |
2023-03-09 |
| Agilent–Exact Sciences: investment, 202309– acquisition €na of Resolution Bioscience by Exact Sciences from Agilent |
2023-09-12 |
| Agilent–Frost & Sullivan: market research, 201906 supply service survey of pharma lab leaders on lab workflows by F&S |
2019-06-04 |
| Agilent–Hamamatsu: digital pathology, 202303– collab distribution of NanoZoomer digital pathology slide scanners by Agilent |
2023-03-10 |
| Agilent–Imperial College: analytical technology, 201802– collab with new Agilent sponsored Measurement Site at ICL incl demo + showcasing solutions |
2018-02-28 |
| Agilent–Insight Experience: human capital management, –201801 supply service co-developm of Agilent’s Emerging Leaders Program |
2018-01-30 |
| Agilent–Mettler-Toledo: lab automation, –202206 collab developm + product integration automated + digitalised sample prep for LC/GC workflow |
2022-06-01 |
| Agilent–Mobilion: mass spectrometry, 2018– collab integration of SLIM ion mobility technology with Agilent Q-TOF MS platform |
2018-01-01 |
| Agilent–Nanyang Technological Univ: water analysis, 201807– collab developm of new approaches to test + monitor regional water supply with NEWRI |
2018-07-09 |
| Agilent–Plasmion: ionisation technology, 202301– collab co-marketing of SICRIT ion source with Agilent Ultivo LC/TQ + LC/MSD iQ MS systems |
2023-01-18 |
| Agilent–Proscia: digital pathology, 202303– collab ww distribution multi-year for Concentriq Dx platform with Agilent digital pathology solutions |
2023-03-08 |
| Agilent–Scitara: lab informatics, 202209– collab product integration of OpenLab CDS + SLIMS with Scientific Integration Platform SIP + DLX |
2022-09-21 |
| Agilent–SEVERAL: credit, 201909–202909 public offering $500m net $492.8m Senior Notes 2.75% due Sept 2029 |
2019-09-05 |
| Agilent–Univ Duisburg-Essen: analytical technology, 201804– collab with new Agilent sponsored Teaching + Research Center for Separation (TRC) at UDE |
2018-05-24 |
| Agilent–Univ Michigan: analytical chemistry, 201804 long-term collab existent in area of chemical measurement science |
2018-04-25 |
| Agilent–Univ Southern California: laboratory equipment, 201801– collab establ Center of Excellence in Biomolecular Charaterization at USC |
2018-01-29 |
| Agilent–Visiopharm: image analysis software, 202003– collab co-marketing of Visiopharm’s AI-driven solutions for digital pathology |
2020-03-02 |
| Agomab Therapeutics–Advent France Biotechnology: investment, 202103 financing round Series B totalling $74m incl existing + co-investor AFB |
2021-03-10 |
![[LSUS] Life-Sciences-USA.com - The Transatlantic Life Sciences Web Portal](/images/basics/lsus-life-sciences-usa-portal-logo.svg){kind=logo}
1 2 3 4 ... 74 75 76 
![Picture [iito] [LSE] Life-Sciences-Europe.com Business Portal 650x200px](/banner/iito-business-intelligence-20220406-650-200-lse-life-sciences-europe.jpg)
![Picture [iito] LSE iitoLifeScience Life Sciences Mass Spec 120x120px](/banner/iito-business-intelligence-20230710-120-120-twitter-iitolifescience-germany-europe-mass-spec.jpg)
![Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px](/banner/iito-20150801-120-600-lse-life-sciences-europe-com.jpg)
